mCRPC VL

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide in the High-risk Nonmetastatic Castration-resistant Prostate Cancer - Charles Ryan

Details
Journal Club: Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. European Urology Charles Ryan, MD discusses the androgen receptor antagonist apalutamide was safe in patients with high-risk nonmetastatic castration-resistant prostate cancer and, based on dura...

IMAAGEN Trial Update: Effect of Abiraterone Acetate and Low Dose Prednisone on PSA in Patients with Non-Metastatic Castration-Resistant Prostate Cancer - Charles Ryan

Details
Charles Ryan presents an update to the IMAAGEN Trial which includes the percentage of patients with event-free rates for PSA progression at 12, 18, and 24 months and radiographic evidence of disease progression with non-metastatic castration-resistant prostate cancer when taking abiraterone acetate and low dose predisone. Biography Charles J. Ryan, MD

Abiraterone in Elderly Chemotherapy-Naive Patients with mCRPC - Charles Ryan

Details
Charles J. Ryan, MD. - Journal Club: Efficacy and Safety of Abiraterone Acetate in Elderly Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Article Abstract: Purpose: Metastatic castration-resistant prostate cancer primarily affects elderly men. In this post hoc analysis we investigated the safety and efficacy of abiraterone acetate in elderly (≥75 years) and younge...

Charles Ryan on mCRPC Treatment: Combination Therapy - Clinical Case

Details
A clincial patient case from Charles Ryan, MD. Professor of Clinical Medicine and Urology, Department of Medicine, UCSF, Program Leader, Genitourinary Medical Oncology, UCSF Thomas Perkins Distinguished Professor in Cancer Research, UCSF Biography: Dr. Ryan is Professor of Clinical Medicine and Urology at the UCSF Helen Diller Family Comprehensive Cancer Center where he is the Clinical Program Lea...

Assessment of Corticosteroid-Associated Adverse Events With Long Term Exposure to Low-Dose Prednisone Given With Abiraterone Acetate to mCRPC Patients - Charles Ryan

Details
Assessment of Corticosteroid-Associated Adverse Events With Long Term Exposure to Low-Dose Prednisone Given With Abiraterone Acetate to mCRPC Patients presented by Charles Ryan, MD.

Delay Chemotherapy in Hormone Sensitive Metastatic Prostate Cancer - Michael Cookson

Details
Delay Chemotherapy in Hormone Sensitive Metastatic Prostate Cancer State of the Art presentation by Michael Cookson, MD. with interview by E. David Crawford, MD. Michael Shawn Cookson, M.D., M.M.H.C., is Professor and Chairman of the Department of Urology at the University of Oklahoma College of Medicine. He holds the Donald D. Albers Endowed Chair in Urology. A graduate of the University of Oklah...

Peter Scardino on A Century of Progress in Urologic Cancers 1915-2015 - MSKCC

Details
Peter Scardino, Chair, Department of Surgery; David H. Koch Chair, shares the illustrious history of urologic oncology at MSKCC and discusses the upcoming Memorial Sloan Kettering Centennial Conference, Modern Management of Urologic Cancers: A Multidisciplinary Approach. Thomas Keane interviews Peter Scardino about the contrubtions and accomplishments to the field of urologic oncology at Memorial...

Charles Ryan on Practical Considerations in the Use of Novel Hormone Agents in the Post-ADT Setting

Details
Practical Considerations in the Use of Novel Hormone Agents in the mCRPC Patient Dr. Ryan delivers a concise presentation on clinical considerations in selecting treatment for the mCRPC patient. He walks though discussions on the Right Patient - the Right Therapy - Right Time - Right Patient. He also presents his objectives in determining treatment after ADT fails on its own. He looks to Preserve...

William Lowrance on AUA Guideline: Castration-resistant Prostate Cancer Update

Details
AUA Guideline: Castration-resistant Prostate Cancer Update - 2015 Presentation providing the updates and the potential treatment impact on the defined index patient types. William Lowrance, MD, MPH Assistant Professor, Division of Urology University of Utah School of Medicine Salt Lake City, UT The original systematic review and meta-analysis of the published literature yielded 303 studies publish...